PD39-11 48-MONTH DATA FOR THE ADVANCE XP® MALE SLING IN THE THERAPY OF MALE URINARY INCONTINENCE: RESULTS OF A PROSPECTIVE MULTICENTRE STUDY

Abstract

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Male Incontinence: Therapy II1 Apr 2018PD39-11 48-MONTH DATA FOR THE ADVANCE XP® MALE SLING IN THE THERAPY OF MALE URINARY INCONTINENCE: RESULTS OF A PROSPECTIVE MULTICENTRE STUDY Jan-Niclas Mumm, Benedikt Klehr, Alexander Kretschmer, Theresa Vilsmaier, Gerald Schulz, Christian Gozzi, Peter Rehder, Florian May, Roland Homberg, Peter Gebhartl, Christian Stief, and Ricarda Bauer Jan-Niclas MummJan-Niclas Mumm More articles by this author , Benedikt KlehrBenedikt Klehr More articles by this author , Alexander KretschmerAlexander Kretschmer More articles by this author , Theresa VilsmaierTheresa Vilsmaier More articles by this author , Gerald SchulzGerald Schulz More articles by this author , Christian GozziChristian Gozzi More articles by this author , Peter RehderPeter Rehder More articles by this author , Florian MayFlorian May More articles by this author , Roland HombergRoland Homberg More articles by this author , Peter GebhartlPeter Gebhartl More articles by this author , Christian StiefChristian Stief More articles by this author , and Ricarda BauerRicarda Bauer More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1923AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES In recent years, several studies showed already the effectiveness and safety of the AdVance XP male sling in a short follow-up. Aim of this study was to evaluate the safety and effectiveness of the AdVance XP in a prospective multicentre long term follow-up study. METHODS 115 patients with persistent stress urinary incontinence after radical prostatectomy were included. Patients with previous urinary incontinence (UI) surgery, previous radiotherapy, nocturnal UI and a functional urethra < 1cm in the preoperative repositioning test were excluded. Postoperatively, a standardised 24-h pad test, quality-of-life scores [International Quality of Life score (IQOL) and International Consultation on Incontinence Questionnaire short form (ICIQ-UI SF)], visual analogue scale (VAS) for pain, five-item version of the International Index of Erectile Function (IIEF-5), International Prostate Symptom Score (IPSS) and Patient Global Impression of Improvement (PGI-I) score were carried out. The patient collective defined as cured were those patients with a pad test = 0-5 g and no pad usage. The patient group described as improved showed a reduction of urine loss of >50%. All others were classified as failures. Significance analysis was performed using the Wilcoxon test. RESULTS The mean preoperative urine loss in the 24-h pad test was 341g (median 272.0 g). After a follow-up of 12months (112 patients), 64,3% of the patients were cured and 29.5% had improved. The mean urine loss decreased significantly to 19.1 g (P < 0.001), with a mean VAS score of 0.3, and mean PGI-I of 1.4. After a follow-up of 36 months (69 patients), 65,2% of the patients were cured and 23.2% had improved. The mean urine loss decreased significantly to 21.4 g (P < 0.001), with a mean VAS score of 0.0, and mean PGI-I of 1.7. The mean IQOL and ICIQ-UI SF improved significantly (both P < 0.001) after 36 months. After a follow-up of 48 months (42 patients), 73,8% of the patients were cured and 9,5% had improved. The mean urine loss decreased significantly to 13 g (P < 0.001), with a mean VAS score of 0.1, and mean PGI-I of 1.4. The mean IQOL and ICIQ-UI SF improved significantly (both P < 0.001) after 48 months. Until now, no patient were lost to follow-up. There were no significant postoperative changes in IIEF-5 and IPSS. No intraoperative and no long-term complications occurred. No erosion or explantation occurred. CONCLUSIONS The 48 months follow up results demonstrate good and stable effectiveness, low complication rate and considerably improved quality life scores in the use of the AdVance XP. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e802 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Jan-Niclas Mumm More articles by this author Benedikt Klehr More articles by this author Alexander Kretschmer More articles by this author Theresa Vilsmaier More articles by this author Gerald Schulz More articles by this author Christian Gozzi More articles by this author Peter Rehder More articles by this author Florian May More articles by this author Roland Homberg More articles by this author Peter Gebhartl More articles by this author Christian Stief More articles by this author Ricarda Bauer More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...